Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
November 06 2018 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s
biopharmaceutical company, today announced that it will host a
conference call and live webcast at 8:30 a.m. Eastern Time on
Tuesday, November 13, 2018, to provide a corporate update and to
discuss the Company's financial results for the quarter ended
September 30, 2018.
To access the conference call via phone, dial (844) 831-3031
(domestic) or (443) 637-1284 (International). The conference ID
number for the call is 5463588. The live webcast can be accessed
under “Events & Presentations" in the Investor Relations
section of the Company's website at www.darebioscience.com. Please
log in approximately 5-10 minutes prior to the event to register
and to download and install any necessary software. To access
the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is
5463588. The telephone and webcast replay will be available
until November 20, 2018.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
reproductive and sexual health. The company’s mission is to
identify, develop and bring to market a portfolio of novel,
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women in the areas of
contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes two potential first-in-class
candidates currently in clinical development: Ovaprene®, a
non-hormonal, monthly contraceptive vaginal ring, and Sildenafil
Cream, 3.6%, a potential treatment for female sexual arousal
disorder utilizing the same active ingredient as Viagra®. To learn
more about Daré’s full portfolio of women’s health products, and
mission to deliver novel therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré uses these channels to
communicate with its investors and the public about the company and
other company-related matters. The information Daré posts on its
investor relations website may be deemed to be material
information. Daré encourages investors, the media, and others
interested in the company to review the information Daré posts on
its investor relations website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Ami
BavishiBurns McClellanabavishi@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda
GuisbondCanale Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024